Compare NATH & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATH | AVXL |
|---|---|---|
| Founded | 1916 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.6M | 397.6M |
| IPO Year | N/A | N/A |
| Metric | NATH | AVXL |
|---|---|---|
| Price | $95.22 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 50.8K | ★ 4.1M |
| Earning Date | 11-06-2025 | 11-25-2025 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | ★ 4.02 | N/A |
| EPS | ★ 5.56 | N/A |
| Revenue | ★ $154,991,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | ★ 7.82 | N/A |
| 52 Week Low | $75.15 | $2.86 |
| 52 Week High | $118.50 | $14.44 |
| Indicator | NATH | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 36.99 |
| Support Level | $88.67 | $3.96 |
| Resistance Level | $97.34 | $4.88 |
| Average True Range (ATR) | 3.30 | 0.41 |
| MACD | 0.76 | 0.20 |
| Stochastic Oscillator | 71.64 | 55.44 |
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.